
<!DOCTYPE html>

<html lang="en">
<head id="ctl00_ctl00_Head1"><meta charset="utf-8"/><meta content="width=device-width, initial-scale=1.0" name="viewport"/><meta content="IE=edge" http-equiv="X-UA-Compatible"/><title>
	Clinical Practice Guidelines : Antifungal prophylaxis for children with cancer or undergoing haematopoietic stem cell transplant
</title><link href="/WorkArea/FrameworkUI/css/ektron.stylesheet.ashx?id=-1759591071+-300771134+1985268503" rel="stylesheet" type="text/css"/><link href="/TemplateAssets/stylesheets/bootstrap.css?v=180131" rel="stylesheet"/><link href="/TemplateAssets/stylesheets/bootstrap-rch.css?v=180131" rel="stylesheet"/><link href="/TemplateAssets/stylesheets/print.css?v=180131" media="print" rel="stylesheet" type="text/css"/>




<style>
		.rch-emg-top-banner {
		  background: #DA1A31;
		  margin: 0;
		  padding:10px; 
		  text-align: center;
		  font-weight: 400;
		  color: #fff;
		  font-size:13px;
		}
		
		.rch-emg-top-banner a {
			color: #fff;
		}
		
       </style>





<link href="/TemplateAssets/stylesheets/Open_Sans/fonts.css" rel="stylesheet" type="text/css"/><link href="/apple-touch-icon.png" rel="apple-touch-icon" sizes="180x180"/><link href="/favicon-32x32.png" rel="icon" sizes="32x32" type="image/png"/><link href="/favicon-16x16.png" rel="icon" sizes="16x16" type="image/png"/><link href="/manifest.json" rel="manifest"/><link color="#5bbad5" href="/safari-pinned-tab.svg" rel="mask-icon"/><meta content="#ffffff" name="theme-color"/>










</head>
<body class="rch-section-health-pro">
<form action="/clinicalguide/guideline_index/Antifungal_prophylaxis_for_children_with_cancer_or_undergoing_haematopoietic_stem_cell_transplant/" id="aspnetForm" method="post">
<div class="aspNetHidden">


</div>

<div class="aspNetHidden">


</div>
<div>
<div>

<div class="ektron-ux-UITheme ux-app-siteApppageBuilder-setSizeTemplate">
</div>

</div>
</div>

<div class="container">
<div class="row hidden-xs" id="rch-header" style="height:116px">
<div class="col-xs-12">
<div id="rch-brand">
<a href="https://www.rch.org.au/" onclick="ga('rchTracker.send', 'event', 'navigation', 'click', 'Home-icon');"><img alt="The Royal Children's Hospital Melbourne" class="rch-logo" src="https://www.rch.org.au/TemplateAssets/images/global/RCH-Brandmark.png"/></a>
<h1 class="rch-wai"><a href="https://www.rch.org.au/">The Royal Children's Hospital Melbourne</a></h1>
</div>
<ul id="rch-mini-nav">
<li><a href="https://www.rch.org.au/home/" onclick="ga('rchTracker.send', 'event', 'navigation', 'click', 'Home-mini');"> Home</a></li>
<li><a href="https://www.rch.org.au/rch/about/" onclick="ga('rchTracker.send', 'event', 'navigation', 'click', 'About');">About</a></li>
<li><a href="http://blogs.rch.org.au/news/" onclick="ga('rchTracker.send', 'event', 'navigation', 'click', 'News');">News</a></li>
<li><a href="https://www.rch.org.au/careers/" onclick="ga('rchTracker.send', 'event', 'navigation', 'click', 'Careers');">Careers</a></li>
<li><a href="https://shop.rch.org.au/" onclick="ga('rchTracker.send', 'event', 'navigation', 'click', 'Shop');">Shop</a></li>
<li><a href="https://www.rch.org.au/rch/contact/" onclick="ga('rchTracker.send', 'event', 'navigation', 'click', 'Contact');">Contact</a></li>
<li class="pull-right"><a class="quicklink-link" href="https://myrchportal.rch.org.au/" onclick="ga('rchTracker.send', 'event', 'navigation', 'click', 'My RCH Portal');">My RCH Portal</a></li>
</ul>

</div>
</div>
<div class="row" id="primary-nav">
<div class="col-sm-11 navbar navbar-default rch-main-nav">
<div class="navbar-header">
<button class="navbar-toggle" data-target=".navbar-collapse" data-toggle="collapse" type="button">
<span class="icon-bar"></span><span class="icon-bar"></span><span class="icon-bar"></span>
</button>
<a aria-label="Search the site" class="navbar-toggle navbar-search-button" href="https://www.rch.org.au/search/" onclick="ga('rchTracker.send', 'event', 'navigation', 'click', 'Search-direct');" type="btn button">
<span class="glyphicon glyphicon-search"></span>
</a>
<a class="navbar-brand img-responsive" href="https://www.rch.org.au/"><img alt="RCH logo" src="https://www.rch.org.au/TemplateAssets/images/global/RCH_logo_navbar.png"/></a>
</div>
<div class="navbar-collapse collapse">
<ul class="nav nav-justified hidden-xs">
<li class="main-nav-4"><a href="https://www.rch.org.au/rch/health-professionals/" onclick="ga('rchTracker.send', 'event', 'navigation', 'click', 'Health Professionals');">Health Professionals</a></li>
<li class="main-nav-1"><a href="https://www.rch.org.au/rch/patients-families/" onclick="ga('rchTracker.send', 'event', 'navigation', 'click', 'Patients and Families');">Patients and Families</a></li>
<li class="main-nav-3"><a href="https://www.rch.org.au/rch/departments/" onclick="ga('rchTracker.send', 'event', 'navigation', 'click', 'Departments and Services');">Departments and Services</a></li>
<li class="main-nav-5"><a href="https://www.rch.org.au/research/" onclick="ga('rchTracker.send', 'event', 'navigation', 'click', 'Research');">Research</a></li>
</ul>
<ul class="nav visible-xs">
<li class="main-nav-1"><a href="https://www.rch.org.au/rch/health-professionals/"><span class="glyphicon glyphicon-chevron-right rch-orange" onclick="ga('rchTracker.send', 'event', 'navigation', 'click', 'Health Professionals');"></span> Health Professionals</a></li>
<li class="main-nav-2"><a href="https://www.rch.org.au/rch/departments/" onclick="ga('rchTracker.send', 'event', 'navigation', 'click', 'Departments and Services');"><span class="glyphicon glyphicon-chevron-right rch-green"></span> Departments and Services</a></li>
<li class="main-nav-3"><a href="https://www.rch.org.au/rch/patients-families/" onclick="ga('rchTracker.send', 'event', 'navigation', 'click', 'Patients and Families');"><span class="glyphicon glyphicon-chevron-right rch-blue"></span> Patients and Families</a></li>
<li class="main-nav-5"><a href="https://www.rch.org.au/research/" onclick="ga('rchTracker.send', 'event', 'navigation', 'click', 'Research');"><span class="glyphicon glyphicon-chevron-right rch-yellow"></span> Research</a></li>
<li class="main-nav-compact"><a href="https://www.rch.org.au/home/" onclick="ga('rchTracker.send', 'event', 'navigation', 'click', 'Home-mini');">Home</a></li>
<li class="main-nav-compact"><a href="https://www.rch.org.au/rch/about/" onclick="ga('rchTracker.send', 'event', 'navigation', 'click', 'About');">About</a></li>
<li class="main-nav-compact"><a href="http://blogs.rch.org.au/news/" onclick="ga('rchTracker.send', 'event', 'navigation', 'click', 'News');">News</a></li>
<li class="main-nav-compact"><a href="https://www.rch.org.au/careers/" onclick="ga('rchTracker.send', 'event', 'navigation', 'click', 'Careers');">Careers</a></li>
<li class="main-nav-compact"><a href="https://www.rch.org.au/rch/support/" onclick="ga('rchTracker.send', 'event', 'navigation', 'click', 'Support');">Support us</a></li>
<li class="main-nav-compact"><a href="https://www.rch.org.au/rch/contact/" onclick="ga('rchTracker.send', 'event', 'navigation', 'click', 'Contact');">Contact</a></li>
</ul>
</div>
</div>
<div class="col-sm-1 hidden-xs" id="nav-search-icon">
<a aria-label="Open search form" href="https://www.rch.org.au" onclick="ga('rchTracker.send', 'event', 'navigation', 'click', 'Search-form');"><span class="glyphicon glyphicon-search"></span></a>
</div>
<div class="hidden-xs" id="search-field">
<div class="form-inline" role="form">
<div class="form-group">
<label class="sr-only" for="search-field">Search</label>
<div id="ctl00_ctl00_SearchPanelTop">





</div>
</div>
</div>
</div>
</div>
<div class="row hidden-xs" id="hero-row">
<div class="col-xs-12">
</div>
</div>
<div class="row" id="custom-row">
<div class="col-12">
</div>
</div>
<div class="row" id="title-row">
<div class="col-xs-12">
<div class="panel panel-default">
<div class="panel-body">
<h2>Clinical Practice Guidelines</h2>
<div class="hidden-md hidden-lg" id="titleblock-section-nav">
<div class="btn-group">
<button class="btn btn-primary dropdown-toggle" data-toggle="dropdown" type="button">
<span class="sr-only">Toggle section navigation</span>
<span class="visible-sm">
<span class="icon-bar"></span>
<span class="icon-bar"></span>
<span class="icon-bar"></span>
</span>
<span class="visible-xs">
<span class="icon-bar"></span>
<span class="icon-bar"></span>
<span class="icon-bar"></span>
</span>
</button>
<ul class="dropdown-menu">
<span class="nav-header">In this section</span>
<li>
<a href="https://www.rch.org.au/clinicalguide/About_Clinical_Practice_Guidelines/ ">
                                                About Clinical Practice Guidelines                                   
                                                </a>
</li>
<li>
<a href="https://www.rch.org.au/clinicalguide/ ">
                                                CPG index                                   
                                                </a>
</li>
<li>
<a href="https://www.rch.org.au/rchcpg/hospital_clinical_guideline_index/Nursing_guidelines_index/ ">
                                                Nursing Guidelines                                   
                                                </a>
</li>
<li>
<a href="https://www.rch.org.au/clinicalguide/about_rch_cpgs/Paediatric_Improvement_Collaborative/ ">
                                                Paediatric Improvement Collaborative                                   
                                                </a>
</li>
<li>
<a href="https://www.rch.org.au/clinicalguide/guideline_index/Parent_resources/ ">
                                                Parent resources                                   
                                                </a>
</li>
<li>
<a href="https://www.rch.org.au/clinicalguide/guideline_index/Retrieval_services/ ">
                                                Retrieval services                                   
                                                </a>
</li>
<li>
<a href="https://www.rch.org.au/clinicalguide/guideline_index/CPG_Committee_Calendar/ ">
                                                CPG Committee Calendar                                   
                                                </a>
</li>
<li>
<a href="https://www.rch.org.au/clinicalguide/about_rch_cpgs/CPG_information/ ">
                                                CPG information                                   
                                                </a>
</li>
<li>
<a href="https://www.rch.org.au/clinicalguide/about_rch_cpgs/Other_resources/ ">
                                                Other resources                                   
                                                </a>
</li>
<li>
<a href="https://www.rch.org.au/clinicalguide/forms/feedback/ ">
                                                CPG feedback                                   
                                                </a>
</li>
</ul>
</div>
</div>
</div>
</div>
<span class="breadcrumb hidden-xs">
<span id="ctl00_ctl00_rchFolderBreadCrumb"><a href="https://www.rch.org.au/" target="_self" title="The Royal Children&amp;#39;s Hospital">RCH</a>  &gt;  <a href="https://www.rch.org.au/rch/health-professionals/" target="_self" title="Health Professionals">Health Professionals</a>  &gt;  <a href="https://www.rch.org.au/clinicalguide/" target="_self" title="Clinical Practice Guidelines">Clinical Practice Guidelines</a>  &gt;  <a href="https://www.rch.org.au/clinicalguide/guideline_index/Antifungal_prophylaxis/" target="_self" title="&lt;p&gt;&lt;br/&gt;&lt;/p&gt;">Antifungal prophylaxis for children with cancer or undergoing haematopoietic stem cell transplant</a></span>
</span>
</div>
</div>
<div class="row" id="content-row">

<div class="col-md-2 hidden-xs hidden-sm hidden-print" id="rch-secondary" role="complementary">
<p class="nav-header">In this section</p>
<ul class="nav sm sm-vertical" id="rch-sidenav">
<li>
<a class="" href="https://www.rch.org.au/clinicalguide/About_Clinical_Practice_Guidelines/ ">About Clinical Practice Guidelines</a>
</li>
<li>
<a class="" href="https://www.rch.org.au/clinicalguide/ ">CPG index</a>
</li>
<li>
<a class="" href="https://www.rch.org.au/rchcpg/hospital_clinical_guideline_index/Nursing_guidelines_index/ ">Nursing Guidelines</a>
</li>
<li>
<a class="" href="https://www.rch.org.au/clinicalguide/about_rch_cpgs/Paediatric_Improvement_Collaborative/ ">Paediatric Improvement Collaborative</a>
</li>
<li>
<a class="" href="https://www.rch.org.au/clinicalguide/guideline_index/Parent_resources/ ">Parent resources</a>
</li>
<li>
<a class="" href="https://www.rch.org.au/clinicalguide/guideline_index/Retrieval_services/ ">Retrieval services</a>
</li>
<li>
<a class="" href="https://www.rch.org.au/clinicalguide/guideline_index/CPG_Committee_Calendar/ ">CPG Committee Calendar</a>
</li>
<li>
<a class="" href="https://www.rch.org.au/clinicalguide/about_rch_cpgs/CPG_information/ ">CPG information</a>
</li>
<li>
<a class="" href="https://www.rch.org.au/clinicalguide/about_rch_cpgs/Other_resources/ ">Other resources</a>
</li>
<li>
<a class="" href="https://www.rch.org.au/clinicalguide/forms/feedback/ ">CPG feedback</a>
</li>
</ul>
</div>
<div class="col-md-10" id="rch-primary">
<div class="row visible-print" id="print-header" style="margin-left: 0; margin-right: 0;">
<div class="col-xs-9">
<h1>Antifungal prophylaxis for children with cancer or undergoing haematopoietic stem cell transplant</h1>
</div>
<div class="col-xs-3">
<img alt="RCH Logo" class="pull-right img-responsive" src="https://www.rch.org.au/TemplateAssets/images/global/RCH-Master-500-000.png" style="margin:20px;" width="140"/>
</div>
</div>
<div>
<h1 class="hidden-print">Antifungal prophylaxis for children with cancer or undergoing haematopoietic stem cell transplant</h1>
<span id="ctl00_ctl00_plhContent_plhContentBody_lblErrorMessage"></span>
<div class="" id="ctl00_ctl00_plhContent_plhContentBody_DropZone1_uxUpdatePanel">
<div data-ux-pagebuilder="DropZone" id="ctl00_ctl00_plhContent_plhContentBody_DropZone1_uxDropZone">
<div data-ux-pagebuilder="Column" style="width:100%">
<ul role="presentation">
<li role="presentation">
<div id="ctl00_ctl00_plhContent_plhContentBody_DropZone1_uxColumnDisplay_ctl00_uxControlColumn_ctl00_uxWidgetHost_uxUpdatePanel">
<div data-ux-pagebuilder="Widget">
<div class="widgetBody">
<div id="ctl00_ctl00_plhContent_plhContentBody_DropZone1_uxColumnDisplay_ctl00_uxControlColumn_ctl00_uxWidgetHost_uxWidgetHost_widget_CB">
<div class="row">
<div class="col-md-2">
<br/>
<img alt="Statewide logo" class="fancy" draggable="true" src="https://www.rch.org.au/uploadedImages/Main/Content/clinicalguide/guideline_index/Victoria-State-Gov-logo-black-rgb.png" title="Statewide logo">
</img></div>
<div class="col-md-10">
<h3>This guideline has been adapted for statewide use with the support of the Victorian Paediatric Clinical Network</h3> </div> </div>
</div>
<span id="ctl00_ctl00_plhContent_plhContentBody_DropZone1_uxColumnDisplay_ctl00_uxControlColumn_ctl00_uxWidgetHost_uxWidgetHost_widget_errorLb"></span>
</div>
</div>
</div>
</li>
<li role="presentation">
<div id="ctl00_ctl00_plhContent_plhContentBody_DropZone1_uxColumnDisplay_ctl00_uxControlColumn_ctl01_uxWidgetHost_uxUpdatePanel">
<div data-ux-pagebuilder="Widget">
<div class="widgetBody">
<div id="ctl00_ctl00_plhContent_plhContentBody_DropZone1_uxColumnDisplay_ctl00_uxControlColumn_ctl01_uxWidgetHost_uxWidgetHost_widget_CB">
<h2>See also</h2>
<p>
<a href="https://www.rch.org.au/clinicalguide/guideline_index/Fever_and_suspected_or_confirmed_neutropenia/">Fever and suspected or confirmed neutropenia</a>
</p>
<h2>
Key points</h2>
<ol start="1" type="1"><li>Appropriate      antifungal prophylaxis is an important component of cancer care</li><li>Antifungal      prophylaxis has been shown to reduce the risk of invasive fungal infection      (IFI) in selected high-risk children.</li><li>Where      possible, an azole agent is preferred and therapeutic drug monitoring      should be done for posaconazole, voriconazole and itraconazole.                                                                          
        <br/></li></ol>
<h2><b><a data-ektron-placeholder="bookmark" id="background" title="background"></a>Background</b></h2>
<p><span></span>
</p>
<p>Children with cancer are at varying risk of invasive fungal infection (IFI). Factors that influence this risk include type of cancer, chemotherapy protocol, depth and duration of neutropaenia, steroid exposure and previous history of IFI. Antifungal prophylaxis has been shown to reduce the
                                    risk of developing an IFI and can be broadly divided into mould-active (ie against <i>Aspergillus</i> spp.) and non-mould active (ie against <i>Candida</i> spp.) prophylaxis.                                          
    <br/>
</p>
<p>Primary antifungal prophylaxis is recommended when the underlying incidence of IFI exceeds 10%. When implementing prophylaxis regimens, consideration must also be given to institutional epidemiology and relevant adjustments made.                       
                                   
    <br/>
</p>
<h2><b>Assessment</b></h2>
<p>
</p><ul type="disc"><li>Prophylaxis      recommendations are based on underlying risk of IFI </li><li>The type of      prophylaxis (mould versus non-mould active) varies according to cancer      diagnosis associated complications and/or treatment phases </li><li>Children at      high and intermediate risk for IFI should receive appropriate prophylaxis            
        <br/></li></ul>
<p><b>Table
1:</b> Stratification of risk of IFI in children with cancer/Haematopoietic Stem Cell Transplant (HSCT) </p>
<p>
</p><table class="table table-striped table-bordered table-hover" dropzone="copy">
<tbody>
<tr>
<td style="cursor: default;"> <b>Risk Stratum</b> </td>
<td style="cursor: default;"> <b>Risk of IFI with</b> </td>
<td style="cursor: default;"> <b>Patient Population</b> </td> </tr>
<tr>
<td rowspan="2" style="cursor: default;">  High Risk (≥10%)        </td>
<td style="cursor: default;"> <b>Mould &gt; Yeast</b>      </td>
<td style="cursor: default;">
<p>High risk/very high risk acute lymphoblastic leukaemia (ALL) in intensive treatment phases</p><p>Acute myeloid leukaemia (AML)</p><p>Relapsed acute leukaemia (ALL and AML)</p>
<p>Allogeneic HSCT with acute Grade   II-IV GvHD </p>
<p>Allogeneic HSCT chronic extensive   GvHD</p>
<p>Severe aplastic anaemia </p> </td> </tr>
<tr>
<td style="cursor: default;"> <b>Yeast &gt; Mould </b>      </td>
<td style="cursor: default;">
<p>Allogeneic HSCT (pre-engraftment   phase)</p>      </td> </tr>
<tr>
<td style="cursor: default;">  Intermediate Risk   </td>
<td style="cursor: default;"> <b>Yeast &gt; Mould </b>      </td>
<td style="cursor: default;">  Autologous HSCT (neutropenic phase)       </td> </tr>
<tr>
<td style="cursor: default;">  Low Risk (≤5%)   </td>
<td style="cursor: default;">  -   </td>
<td style="cursor: default;">
<p>Non-relapse ALL (excluding high-risk ALL in intensive phases)</p>
<p>Lymphoma (excluding autologous HSCT)</p>
<p>Solid tumours (excluding autologous HSCT)<span></span> </p> </td> </tr>
<tr>
<td style="cursor: default;">  Sporadic occurrence   </td>
<td style="cursor: default;">  -   </td>
<td style="cursor: default;">
<p>Paediatric solid tumours</p>
<p>Brain tumours</p>
<p>Hodgkin lymphoma</p> </td> </tr> </tbody>
</table>
<h2>Management</h2>
<p>
</p><h3><b>Investigations</b><span></span></h3>
<p>
</p><p>Nil </p>
<p>
</p><p>If a child has a suspected IFI (ie prolonged or recurrent fever), evaluation and empiric treatment should follow the                                    
    <a href="https://www.rch.org.au/clinicalguide/guideline_index/Fever_and_suspected_or_confirmed_neutropenia/">Fever and suspected or confirmed neutropenia</a> recommendations.                                        
    <br/>
</p>
<h3><b><a data-ektron-placeholder="bookmark" id="Primary prophylaxis" title="NewBookmark"></a>Primary prophylaxis</b>
<br/></h3>
<p> <b>Table 2:</b>
<a href="https://www.rch.org.au/uploadedFiles/Main/Content/clinicalguide/guideline_index/Antifungal prophylaxis Table 2(1).pdf" title="Antifungal primary prophylaxis Table 2">Recommended prophylaxis regimens according to patient population</a>
<br/> </p>
<p>Note: Refer to Table 3 for dose and monitoring recommendations.                                     
    <br/>
</p>
<h3><a data-ektron-placeholder="bookmark" id="drug information" title="NewBookmark"></a>Drug information 

 
<br/></h3>
<p><b>Table
3:</b> Antifungal prophylaxis dose, therapeutic drug monitoring (TDM) targets, important food-drug interactions and monitoring recommendations</p>
<p>
</p><table class="table table-striped table-bordered table-hover" dropzone="copy">
<tbody>
<tr>
<td style="cursor: default;"> <b>Antifungal</b> </td>
<td style="cursor: default;"> <b>Dose</b> </td>
<td style="cursor: default;"> <b>Target trough* for prophylaxis</b> </td>
<td style="cursor: default;"> <b>Notes</b> </td> </tr>
<tr>
<td style="cursor: default;">  Fluconazole   </td>
<td style="cursor: default;"><p>  6-12 mg/kg (max 400 mg) oral/IV daily</p><p><b>oral:</b> round to nearest 50 mg capsules</p></td>
<td style="cursor: default;">  Not routinely required   </td>
<td style="cursor: default;">
<p>Administer with or without food</p>
<p>Monitor for rash (rare) and hepatotoxicity (rare)</p><p>Monitor for QT prolongation if other risk factors or pro-arrhythmic   drugs</p><p>Adjust in renal impairment (speak to pharmacy)    </p></td> </tr>
<tr>
<td style="cursor: default;">  Posaconazole           </td>
<td style="cursor: default;">
<p><b>Oral suspension:</b> </p>
<p>≥13 years: 200 mg oral TDS</p>                                                                                                                             
                <p><b>Oral tablets:</b> </p>
<p style="margin: 0px;">≥13 years OR</p><p style="margin: 0px;">≥10 years and weighing </p><p>≥30 kg: 300 mg oral daily</p>      </td>
<td style="cursor: default;">
<p>Trough level &gt;0.7 µg/mL </p>                                                                                                                             
                <p>Take trough level 5-7 days after starting drug or changing dose or formulation</p> </td>
<td style="cursor: default;">
<p style="margin: 0px;">Administer with food. </p>
<p>(absorption ↑with high fat meal)</p>Safety and efficacy in children below the age of 13 years has not been   well established. Variable doses for posaconazole tablets for children &lt;13 years and &lt;30 kg have been described including 200 mg oral daily. Discuss with ID and pharmacy if required<br/>                                                                                                                             
                <p>Monitor for rash (rare), hepatotoxicity (rare), neurotoxicity and GI   upset</p><p>Monitor for QT prolongation if other risk factors or pro-arrhythmic   drugs</p><p>Caution in renal impairment as solubilizer may accumulate, consult pharmacy   </p></td> </tr>
<tr>
<td style="cursor: default;">  Voriconazole       </td>
<td style="cursor: default;">
<p><b>Oral tablets/suspension:</b> </p>
<p>&lt;2 years: discuss with ID and pharmacy</p><p>2 years to                                                                                                                                                    
                    &lt;12 years or 12-14 years and weighing &lt;50 kg: 9 mg/kg   (max 350 mg) oral BD </p>≥15 years or aged 12-14 years and weighing ≥50 kg: 200 mg oral BD<br/>                                                                                                                                                                                     
                        <p><b>Intravenous solution:</b> </p>
<p>&lt;2 years: discuss with ID and pharmacy</p><p>2 years to                                                                                                                                                                                                            
                            &lt;12 years or 12-14 years and weighing &lt;50 kg: 8 mg/kg   (day 1, 9 mg/kg) IV BD </p>≥15 years or aged 12-14 years and weighing ≥50 kg: 4 mg/kg (day 1, 6   mg/kg) IV BD <br/>              </td>
<td style="cursor: default;">
<p>Trough level 1-3 µg/mL** </p>                                                                                                                             
                <p>Take trough level 2-5 days after starting drug or changing dose or formulation</p>                                                                                                                             
                <p>Dose should not be altered if level is 4-6 mg/L and clinical signs of toxicity are not present</p>          </td>
<td style="cursor: default;">
<p>Oral: administer 1 h before or after food (absorption<b> ↓</b> with high fat meals)</p>Council on avoidance sun exposure. Reports of skin cancer with   prolonged (&gt;1 year) use<br/>                                                                                                                             
                <p>Caution   in renal impairment as IV solubilizer may accumulate. Significance is not known,   consult pharmacy<span></span> </p>Monitor for rash, hepatotoxicity, neurotoxicity and visual   disturbances (NB. a trough level &gt;5-6 is   associated with an increased probability of neurological and ocular   toxicity). Visual disturbances are dose related, self-limiting and rarely   require cessation of treatment.<br/>   
                                                                                                                                                                                                                                                         
                <p>Monitor for QT prolongation if other risk factors or pro-arrhythmic   drugs</p> </td> </tr>
<tr>
<td style="cursor: default;">  Itraconazole        </td>
<td style="cursor: default;">
<p><b>Oral solution
  (Sporonox®): </b>2.5 mg/kg oral BD (max 200 mg daily)<b></b> </p>                                                                                                                             
                <p><b>Oral solution
  and capsules are <u>not</u></b> <b>interchangeable. </b>The oral solution is   preferred due to improved bioavailability and as there is limited experience   with capsules in children. If conversion is required, consult pharmacy.</p>          </td>
<td style="cursor: default;">
<p>Trough level &gt;0.5 µg/mL</p>                                                                                                                             
                <p>Take trough level 10-15 days after starting drug or changing dose</p> </td>
<td style="cursor: default;">
<p>Liquid (Sporanox®): administer on an empty stomach at least 1h   before food. Absorption not affected by H2-anagonists</p>Capsules (Sporanox®): administer   with or after food. For children on gastric acid suppressant medications,   separate administration by at least 2 hours and administer with an acidic   beverage (e.g. cola).<br/>                                        
                                                                                                                                                                    
                <p>Monitor for rash, hepatotoxicity, neurotoxicity and GI upset. </p>Monitor for QT prolongation if other risk factors or pro-arrhythmic   drugs<br/>      </td> </tr>
<tr>
<td style="cursor: default;">  Liposomal amphotericin (Ambisome®)   </td>
<td style="cursor: default;"><p>  3 mg/kg IV three times per week <b>(max 100 mg daily)</b></p><p>Ambsiome is available in 50 mg vials (max 100 mg). Where possible round dose to 50 mg ensuring dose is at least 2 mg/kg (max 100 mg)</p></td>
<td style="cursor: default;">  Not required   </td>
<td style="cursor: default;">
<p>Monitor for renal toxicity, electrolyte disturbances (esp.   hypokalaemia and hypomagnesaemia) and hepatotoxicity   
                </p><p>Consider pre/concurrent hydration with 10 mL/kg normal saline   
                </p><p>Consider premedication if infusion related adverse effects (inc.   fever, chills, rigors)   </p></td> </tr>
<tr>
<td style="cursor: default;">  Caspofungin   </td>
<td style="cursor: default;">
<p>1 to 3 months: 25 mg/m<sup>2 </sup>(max 50mg) IV daily   
                </p><p>≥3 months: 50 mg/m<sup>2</sup> (max 50mg) IV daily</p> </td>
<td style="cursor: default;">  Not required   </td>
<td style="cursor: default;">  May cause histamine induced reaction (rash, facial swelling, pruritus   and/or bronchospasm)       </td> </tr>
<tr>
<td style="cursor: default;">  Micafungin   </td>
<td style="cursor: default;"><p>  &lt;4 months age: 2 mg/kg IV daily</p><p>&gt;4 months age: 1 mg/kg (max 50 mg) IV daily   </p></td>
<td style="cursor: default;">  Not required   </td>
<td style="cursor: default;">  May cause histamine induced reaction (rash, facial swelling, pruritus   and/or bronchospasm)       </td> </tr> </tbody>
</table>
<p>
</p><p>*Trough levels for voriconazole, itraconazole and posaconazole are sent to the Alfred hospital and run on a Monday, Tuesday and Thursday (must arrive at The Alfred by 11am). Samples require minimum 1 mL in an EDTA tube.</p>
<p>
</p><p>**A voriconazole trough level &gt;5–6 mg/L is associated with an increased probability of neurological toxicity, including visual disturbances, hallucinations and encephalopathy</p>
<p>
</p><h3><b><a data-ektron-placeholder="bookmark" id="Therapeutic drug monitoring (TDM)" title="NewBookmark"></a>Therapeutic
drug monitoring (TDM)</b></h3>
<p>
</p><p>Itraconazole, voriconazole and posaconazole require TDM </p>
<p>
</p><ul><li>All      children must have TDM</li><li>All patients should have one repeat TDM to confirm stability</li><li>Once      target trough levels are confirmed, repeat TDM is not routinely required </li></ul><p><br/></p><p>Indications      for repeat TDM include</p><ul><li>dose or formulation adjustment (ie iv/oral switch)</li><li>introduction of new drug with potential interactions</li><li>suspected toxicity (always do level before withholding or adjusting dose)</li><li>diagnosis of proven, probable or possible IFI</li></ul><p>
<a data-ektron-placeholder="bookmark" id="Dose adjustments" title="NewBookmark"></a>Dose adjustments should be discussed with oncology pharmacy and/or local infectious diseases unit </p>
<p>
</p><ul type="disc"><li>Depending on      the age of the child, azoles may exhibit nonlinear or linear      pharmacokinetics </li><li>There is also      significant INTER- and INTRA- patient variability with these agents                                                        
        <br/></li></ul>
<p>Prior to any dose adjustment, repeat drug level and ensure the following:</p>
<p>
</p><table class="table table-striped table-bordered table-hover" dropzone="copy">
<tbody>
<tr>
<td style="cursor: default;"> <b>Low azole levels</b> </td>
<td style="cursor: default;"> <b>High azole levels</b> </td> </tr>
<tr>
<td style="cursor: default;">
<ul><li>Confirm true   trough sample was taken</li><li>Confirm   adherence </li><li>Exclude poor   absorption (absorption reduced with severe mucositis and diarrhoea).   Depending on agent, diet may also affect absorption (see Table 3) </li><li>Investigate   potential drug-drug interactions (see below and discuss with pharmacy)</li></ul>               </td>
<td style="cursor: default;">
<ul><li>Confirm a   true trough sample was taken </li><li>Investigate   potential drug-drug interactions (see below and discuss with pharmacy)</li><li>If clinical   signs of toxicity are not present, consider leaving dose regimen unchanged   and monitor potential toxicity carefully. </li></ul>            </td> </tr> </tbody>
</table>
<p>   </p>
<h3><a data-ektron-placeholder="bookmark" id="Secondary prophylaxis" title="NewBookmark"></a>Secondary prophylaxis</h3>
<p><span></span>
</p>
<p>In children with a documented history of <b><i>proven</i></b> or <b><i>probable </i></b>IFI, secondary prophylaxis is required for further cycles of chemotherapy </p>
<p>
</p><ul type="disc"><li>The agent that was      used to treat the initial infection may be used for prophylaxis, provided      it was well tolerated and effective </li><li>Discuss with local      infectious diseases unit          
        <br/></li></ul>
<h4><a data-ektron-placeholder="bookmark" id="Important drug interactions" title="NewBookmark"></a>Important drug interactions for azole antifungal agents<span></span></h4>
<p>The azole class of antifungal agents are metabolised by the cytochrome P450 (CYP450) system. The potential for drug-drug interactions is higher for itraconazole and voriconazole than posaconazole and, in particular, fluconazole.                       
                 
    <br/>
</p>
<p><b>Table 4:</b> Important drug interactions for azole antifungal agents and management recommendations.                                
    <br/>
</p>
<table class="table table-striped table-bordered table-hover" dropzone="copy">
<tbody>
<tr>
<td style="cursor: default;"> <b>Medication</b> </td>
<td style="cursor: default;"> <b>Interaction</b> </td>
<td> <b>Management</b> </td> </tr>
<tr>
<td colspan="3" style="cursor: default;"><b>Decreased plasma concentration of
  azoles</b>      </td> </tr>
<tr>
<td style="cursor: default;"> <b>Rifampicin, rifabutin</b> </td>
<td style="cursor: default;">  Induces azole   metabolism.    </td>
<td rowspan="3" style="cursor: default;">  Avoid   combination where possible. An increase in azole dose may be required       </td> </tr>
<tr>
<td style="cursor: default;"> <b>Carbamazepine</b> </td>
<td rowspan="2" style="cursor: default;">  Induces azole   metabolism (fluconazole, itraconazole, voriconazole)   </td> </tr>
<tr>
<td style="cursor: default;"> <b>Phenobarbitone</b> </td> </tr>
<tr>
<td style="cursor: default;"> <b>Phenytoin</b> </td>
<td style="cursor: default;">  Induces azole   metabolism (itraconazole, voriconazole and posaconazole). Phenytoin   metabolism reduced.    </td>
<td>  Avoid   combination where possible. Monitoring of phenytoin and azole levels recommended.   An increase in azole dose may be required       </td> </tr>
<tr><td style="cursor: default;"><b>Omeprazole and esomeprazole (oral formulations)</b></td><td style="cursor: default;">Liquid posaconazole: PPIs affect gastric pH and reduce posaconazole liquid absorption (less effect on tablets) </td><td style="cursor: default;">Avoid if possible or monitor posaconazole levels </td></tr><tr>
<td colspan="3" style="cursor: default;"> <b>Increased plasma concentration of
  co-administered drug</b>      </td> </tr>
<tr>
<td style="cursor: default;">
<p><b>Vinca alkaloids </b> </p>
<p><b>(vincristine and vinblastine)</b> </p> </td>
<td style="cursor: default;">
<p>Vinca   alkaloid metabolism reduced leading to excess vinca alkaloid exposure   
                </p><p>Cases of   neurotoxicity (peripheral neuropathy, autonomic neuropathy and seizures) have   been reported with vincristine and vinblastine and itraconazole, voriconazole   and posaconazole. Concurrent use with itraconazole leads to earlier and more   severe toxicity  
                                                                                                                                                                                                                        
                </p><p>Electrolyte   abnormalities, hyponatraemia associated with SIADH and GI upset have also   been reported   
                </p><p>Fluconazole   is a weaker CYP3A4 inhibitor so toxicity is rare. </p> </td>
<td style="cursor: default;"><b>
</b><p>Concurrent use   of itraconazole is strictly contraindicated</p><p>Avoid concurrent use of posaconazole where possible (unless advised by infectious diseases and oncology pharmacy)<b>                    </b></p><p>For weekly IV   vinca alkaloid: non-azole agent is preferred<b>   
                </b></p><b><p>For fortnightly or monthly IV vinca alkaloid: withhold voriconazole the day before, the day of and the   day after vinca alkaloid dose. Monitor for toxicity. </p> </b></td> </tr>
<tr>
<td style="cursor: default;"> <b>Tyrosine kinase inhibitors (TKI): (sorafenib,
  imatinib, dasatinib, nioltinib, ceritinib, carfizomib, ruxolitnib)</b> </td>
<td style="cursor: default;">
<p>TKI   metabolism reduced, increasing risk of toxicity including QT prolongation and   cardiac arrhythmias   
                </p><p>Refer to   chemotherapy protocols for detailed management </p> </td>
<td style="cursor: default;">
<p>Concurrent use   of itraconazole, voriconazole and posaconazole is <i>not recommended</i> in most protocols.</p>                                                                                                            
                <p>Fluconazole   can be used in most instances <i>except</i>  in combination with sorafenib. A non-azole agent is mandated for all children   receiving sorafenib. </p> </td> </tr>
<tr><td style="cursor: default;"> <b>Venetoclax</b></td><td style="cursor: default;">Venetoclax metabolism reduced increasing risk of toxicity </td><td style="cursor: default;"><p>Avoid combination</p><p>If unavoidable speak to oncology pharmacy and oncology consultant (venetoclax dose reduction may be required)</p></td></tr><tr>
<td style="cursor: default;"> <b>Bortezomib</b> </td>
<td style="cursor: default;">
<p>Bortezomib   metabolism reduced. </p>                                                                                                            
                <p>Cases of new   or worsening peripheral neurotoxicity have been reported with itraconazole   and voriconazole. </p> </td>
<td style="cursor: default;">
<p>All azoles   should be stopped 72 hours prior to bortezomib dosing and recommenced 72   hours (24 hours for fluconazole) after final dose in course. A non-azole   agent should be substituted during this period.</p>                                        
                                                                                                                                   
                <p>For example,   in children with AML receiving bortezomib on D1 and D8 in a 28-day curse,   substitute fluconazole for an echinocandin on D(-3) to D(+12)</p> </td> </tr>
<tr><td style="cursor: default;"><b>Busulfan, Thiotepa</b></td><td style="cursor: default;">Biosulfan and thiotepa reduced (CYP3A4), leading to significant increases in levels of these drugs </td><td style="cursor: default;">Avoid voriconazole, posaconazole or itraconazole 7 days prior to starting HSCT conditioning (not fluconazole) </td></tr><tr><td style="cursor: default;"><b>Proton pump inhibitors (omeprazole and esomeprazole)</b></td><td style="cursor: default;">Reduced metabolism of voriconazole (CYP2C19), increasing voriconazole levels </td><td style="cursor: default;">Monitor voriconazole levels and signs of toxicity. In particular when starting or stopping the PPI </td></tr><tr>
<td style="cursor: default;"> <b>Sirolimus, Tacrolimus Cyclosporin </b> </td>
<td style="cursor: default;">
<p>Metabolism   reduced, leading to significant increases in levels of these drugs   
                </p><p>Reports of   significantly increased trough concentrations despite dose reduction, due to   combination of itraconazole and sirolimus </p> </td>
<td style="cursor: default;">
<p>Monitor   sirolimus, tacrolimus or cyclosporine levels. Dose reduction usually   required   
                </p><p>Itraconazole   should be used with extreme caution in children on sirolimus </p>      </td> </tr>
<tr>
<td style="cursor: default;"> <b>Diazepam, midazolam</b><span></span> </td>
<td style="cursor: default;">  Metabolism   reduced, increasing risk of toxicity including respiratory depression   </td>
<td style="cursor: default;">  Monitor for   signs of toxicity   </td> </tr>
<tr>
<td colspan="3" style="cursor: default;"> <b>Prolonged QT interval</b>      </td> </tr>
<tr>
<td style="cursor: default;"> <b>Gemtuzumab, macrolide &amp; quinolone antibiotics,
  conventional antipsychotics </b> </td>
<td style="cursor: default;">  Additive risk   of QT prolongation in setting of azole prophylaxis   </td>
<td style="cursor: default;">
<p>Use   combination in caution. Obtain an ECG prior to starting treatment and weekly   thereafter</p>
<p>Azoles should   not be used in children with additional cardiac risk factors including   reduced left ventricular fraction and electrolyte disturbances </p> </td> </tr> </tbody>
</table>
<h2> 
Consider consultation with local paediatric
team when</h2>
<p>
</p><p>All decisions to start and stop antifungal prophylaxis as well as issues with tolerability or side effects should be discussed with the child’s primary treating team.                                 
    <br/>
</p>
<h2><b>Consider transfer when</b></h2>
<p>
</p><p>All suspected or confirmed fungal infections should be discussed with the child’s primary treating team and consideration given to transfer to a tertiary paediatric cancer centre for investigation and management.                                
    <br/>
</p>
<p style="color: rgb(255, 0, 0);">For emergency advice and paediatric or neonatal ICU transfers, call the Paediatric Infant Perinatal Emergency Retrieval (PIPER) Service: 1300 137 650.</p><p style="text-align: right;">
Last Updated May 2021</p>
</div>
<span id="ctl00_ctl00_plhContent_plhContentBody_DropZone1_uxColumnDisplay_ctl00_uxControlColumn_ctl01_uxWidgetHost_uxWidgetHost_widget_errorLb"></span>
</div>
</div>
</div>
</li>
<li role="presentation">
<div id="ctl00_ctl00_plhContent_plhContentBody_DropZone1_uxColumnDisplay_ctl00_uxControlColumn_ctl02_uxWidgetHost_uxUpdatePanel">
<div data-ux-pagebuilder="Widget">
<div class="widgetBody">
<div id="ctl00_ctl00_plhContent_plhContentBody_DropZone1_uxColumnDisplay_ctl00_uxControlColumn_ctl02_uxWidgetHost_uxWidgetHost_widget_CB">
<div class="rch-accordion">
<h2>Reference List</h2>
<div>
<ol>
<li>
  Boonsathorn S. Clinical Pharmacokinetics and Dose Recommendations for Posaconazole in Infants and Children. Clin Pharmacokinet. 2018 </li>
<li> Chau MM et al. Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014. Intern Med J. 2014; v44 </li>
<li> Fleming S et al. Consensus guideline for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, Intern Med J. 2014;44(12b):1283-97</li>
<li> Lehrnbecher T et al. Clinical Practice Guideline for Systemic Antifungal Prophylaxis in Pediatric Patients With Cancer and Hematopoietic Stem-Cell Transplantation Recipients. J Clin Oncol. 2020 Sep 20;38(27):3205-3216</li>
<li> Maertens JA et al. European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. J Antimicrob Chemother. 2018</li>
<li> Tragiannidis A et al. Plasma explosure following posaconazole delayed release tablets in immunocompromised children and adolescents. J Antimicrob Chemother. 2019 <br/>
</li>
</ol>
</div></div>
</div>
<span id="ctl00_ctl00_plhContent_plhContentBody_DropZone1_uxColumnDisplay_ctl00_uxControlColumn_ctl02_uxWidgetHost_uxWidgetHost_widget_errorLb"></span>
</div>
</div>
</div>
</li>
</ul>
</div>
</div>
</div>
<div>
<div id="ctl00_ctl00_plhContent_plhContentBody_cbCpgDis">

</div>
</div>

</div>
<div>
<div id="ctl00_ctl00_plhContent_plhRightCol_ContentBlock1">

</div>
</div>
<span id="ctl00_ctl00_lblErrorMessage"></span>
</div>
</div>
<style>

            

         footer #footer-Wurundjeri {
            background-color: #a2260b;
            color:white;
            font-size:16px;
         }

          footer #footer-row1 {
            background-color: none;
            }
                    
          footer #footer-Wurundjeri-text {
            background-color: none;
            }
                    
          footer #footer-row2 {
            background-color: none;
            }

           footer .footer_iocons1 {

                   display: block;
                   width: auto;
                    height: 35px;
            
            }

           footer .footer_iocons2 {

                   display: block;
                   width: auto;
                    height: 50px;
            
            }


       </style>
<footer>
<div class="row hidden-md hidden-sm hidden-xs" id="footer-Wurundjeri" style="background-color: #a2260b;padding-left: 0px;">
<div class="col-md-3 col-xs-12 social-icons" style="padding-left: 0px;">
<img alt="Wadja logo" class="img-responsive" src="https://www.rch.org.au/uploadedImages/Main/Content/rch/Wadja-footer-artwork-222x60.png"/>
</div>
<div class="col-md-9 col-xs-12" id="footer-Wurundjeri-text" style="margin-top:16px;">
<p>The Royal Children’s Hospital (RCH) acknowledges the traditional owners of the land on which the RCH is situated, the Wurundjeri people of the Kulin Nation, and we pay our respects to their Elders past and present.</p>
</div>
</div>
<div class="row visible-xs" style="background-color: #a2260b;padding-left: 0px;">
<div class="col-xs-12 social-icons" style="padding-left: 0px;padding-right: 0px;">
<img alt="Wadja logo" class="img-responsive" src="https://www.rch.org.au/uploadedImages/Main/Content/rch/Wadja-footer-artwork-390x60(1).png"/>
</div>
<div class="col-xs-12" style="margin-top:16px; color: white;font-size: 16px;}">
<p>The Royal Children’s Hospital (RCH) acknowledges the traditional owners of the land on which the RCH is situated, the Wurundjeri people of the Kulin Nation, and we pay our respects to their Elders past and present.</p>
</div>
</div>
<div class="row visible-sm" style="background-color: #a2260b;padding-left: 0px;">
<div class="col-sm-12 social-icons" style="padding-left: 0px;padding-right: 0px;">
<img alt="Wadja logo" class="img-responsive" src="https://www.rch.org.au/uploadedImages/Main/Content/rch/Wadja-footer-artwork-390x60(1).png"/>
</div>
<div class="col-sm-12" style="margin-top:16px; color: white;font-size: 16px;}">
<p>The Royal Children’s Hospital (RCH) acknowledges the traditional owners of the land on which the RCH is situated, the Wurundjeri people of the Kulin Nation, and we pay our respects to their Elders past and present.</p>
</div>
</div>
<div class="row visible-md" style="background-color: #a2260b;padding-left: 0px;">
<div class="col-md-3 social-icons" style="padding-left: 0px;padding-right: 0px;">
<img alt="Wadja logo" class="img-responsive" src="https://www.rch.org.au/uploadedImages/Main/Content/rch/Wadja-footer-222x94px.png"/>
</div>
<div class="col-md-9" style="margin-top:16px; color: white;font-size: 16px;}">
<p>The Royal Children’s Hospital (RCH) acknowledges the traditional owners of the land on which the RCH is situated, the Wurundjeri people of the Kulin Nation, and we pay our respects to their Elders past and present.</p>
</div>
</div>
<br/><br/>
<div class="row" id="footer-row1" style="background-color:white">
<div class="col-sm-6 col-xs-12 social-icons">
<a href="https://www.facebook.com/rchmelbourne" onclick="ga('rchTracker.send', 'event', 'social', 'click', 'Facebook');" title="Facebook">
<i class="fa fa-facebook-square" style="color:#87946B;font-size:50px;"></i>
</a>
<a href="https://www.instagram.com/rchmelbourne/" onclick="ga('rchTracker.send', 'event', 'social', 'click', 'Instagram');" title="Instagram">
<i class="fa fa-instagram" style="color:#87946B;font-size:50px;"></i>
</a>

<a href="https://www.linkedin.com/company/8333989/" onclick="ga('rchTracker.send', 'event', 'social', 'click', 'LinkedIn');" title="LinkedIn">
<i class="fa fa-linkedin-square" style="color:#87946B;font-size:50px;"></i>
</a>
<a href="https://www.youtube.com/@RCHMelb/videos" onclick="ga('rchTracker.send', 'event', 'social', 'click', 'YouTube');" title="YouTube">
<i class="fa fa-youtube-square" style="color:#87946B;font-size:50px;"></i>
</a>
</div>
<div class="col-sm-6 col-xs-12" id="pig-and-interpreter">
<a href="https://www.rch.org.au/info/az_guide/Interpreter_Services/" onclick="ga('rchTracker.send', 'event', 'footer', 'click', 'Interpreter');" title="Interpreter Services">
<img alt="Interpreter Services" id="footer-interpreter-icon" src="https://www.rch.org.au/uploadedImages/Main/Content/rch/RCH-Interpreter-GumGreen.svg" style="height:50px"/>
</a>
<a href="https://www.rch.org.au/rch/support/" onclick="ga('rchTracker.send', 'event', 'footer', 'click', 'Support us');" title="Support us">
<img alt="Support us" id="footer-support-us" src="https://www.rch.org.au/uploadedImages/Main/Content/rch/RCH-Support-us-GumGreen.svg" style="height:50px"/></a>
</div>
</div>
<div class="row" id="footer-row2" style="background-color:white">
<div class="col-sm-6">
<div class="rch-footer-company" itemscope="" itemtype="http://schema.org/Organization">
<h3 itemprop="name">The Royal Children's Hospital Melbourne</h3>
<p itemprop="telephone" style="margin-bottom: 0px;">Telephone +61 3 9345 5522</p>
<p itemprop="address" itemscope="" itemtype="http://schema.org/PostalAddress"><span itemprop="streetAddress">50 Flemington Road Parkville</span> <span itemprop="addressLocality">Victoria <span itemprop="postalCode">3052</span> Australia</span></p>
</div>
</div>
<div class="rch-footer-company">
<div class="rch-footer-company">
<p class="footertmpright pppp"><a href="https://www.rch.org.au/rch/departments/" onclick="ga('rchTracker.send', 'event', 'footer', 'click', 'Site Map');">Site Map</a> | <a href="https://www.rch.org.au/rch/about/Copyright/" onclick="ga('rchTracker.send', 'event', 'footer', 'click', 'Copyright');">Copyright</a> | <a href="https://www.rch.org.au/rch/about/terms-and-conditions/" onclick="ga('rchTracker.send', 'event', 'footer', 'click', 'Terms and Conditions');">Terms and Conditions</a></p>

<p class="footer-grey footertmpright" style="margin-top:0;margin-bottom:0;">

<span id="Span1" style="display:none;"><br/></span>
<br/><span id="rch-footer-lastupdated"> </span>
</p>
</div>
</div>
</div>
<div class="row" id="footer-row3">
</div>
</footer>
</div>
</form>



</body>
</html>